VALENCIA, Spain, October 11, 2023 /PRNewswire/ — ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on the development of innovative medicines through microRNA modulation, today announced that it will participate in the 3rd 1×1 Virtual Forum Needham Private Biotech Company Annual, taking place October 17-18, 2023. Company management will participate in virtual one-on-one meetings with potential investors during the conference.
ARTHEx’s lead program, ATX-01, is advancing into clinical development for the treatment of myotonic dystrophy type 1 (DM1), a rare progressive neuromuscular disease.
About ARTHEx Biotech
ARTHEx Biotech is a clinical-stage biotechnology company focused on the development of innovative medicines through microRNA modulation. The company’s lead investigational compound, ATX-01, is advancing toward clinical development for the treatment of myotonic dystrophy type 1 (DM1), a rare progressive neuromuscular disease. ARTHEx is also advancing its internal discovery engine to identify and develop microRNA modulators for other disorders with large unmet medical needs, including genetically driven diseases such as T1D. The Company’s headquarters are in Valencia, Spain.
For more information, visit www.arthexbiotech.com and follow us on LinkedIn.
Contact
Frédéric LegrosExecutive President and CEOflegros@arthexbiotech.com 33679495790
Contact investors and media
Amy ConradJuniper Pointamy@juniper-point.com 1 858-366-3243
Logo – https://mma.prnewswire.com/media/2068054…
View original content: https://www.prnewswire.com/es/comunicados-de-prensa/arthex-biotech-participara-en-el-3er-foro-virtual-1×1-anual-de-needham-private-biotech-company-301952686.html
